Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron (Nasdaq: GERN) will release its first quarter 2026 financial results and business highlights before the market opens on May 6, 2026.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time, with live and archived audio available from the Investors and Media section of its website at www.geron.com.
Geron Corporation (Nasdaq: GERN) reported inducement stock option grants effective April 17, 2026, totaling 855,000 shares to nine newly hired employees.
The options carry a $1.68 exercise price (closing price on the grant date), a 10-year term, and vest over four years with a 12.5% six-month cliff.
Geron (Nasdaq: GERN) granted a 2,500,000-share stock option to Timothy Williams as an inducement for joining as Executive Vice President, Chief Legal Officer and Corporate Secretary.
The option was granted April 13, 2026, has a $1.73 exercise price (equal to the grant-date close), a 10-year term and vests over four years with 12.5% vesting at six months.
Geron (Nasdaq: GERN) announced on April 13, 2026 the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. Williams joins Geron after serving as Senior Vice President, General Counsel and Secretary at Vanda Pharmaceuticals from 2018 until March 2026.
Geron said Williams brings deep biopharma legal experience across commercial-stage companies, M&A, corporate governance, securities and compliance, and will support Geron’s strategy in hematology.
Geron (Nasdaq: GERN) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:00 a.m. ET. A live audio webcast and archived audio will be available via the Investors & Media section at geron.com.
Geron (Nasdaq: GERN) appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors on March 26, 2026.
Both appointees bring decades of biopharmaceutical leadership and commercial-stage experience and will support Geron's commercial strategy to drive growth for RYTELO.
Geron (Nasdaq: GERN) granted inducement stock options effective March 17, 2026, to six newly hired employees totaling 956,250 shares.
The options carry an exercise price of $1.62 (the closing price on the grant date), a 10-year term, and vest over four years (12.5% at six months, remainder monthly over 42 months), granted under Nasdaq Rule 5635(c)(4) and Geron’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) reported RYTELO (imetelstat) net product revenue of $48.0M in Q4 2025 and $183.6M for full year 2025, with year-end cash and marketable securities of $401.1M. Total operating expenses for 2025 were $254.7M. For 2026 the company reiterated guidance of $220M–$240M RYTELO revenue and $230M–$240M operating expenses and expects current cash plus anticipated net revenues to fund operations.
Geron noted a 9% quarterly demand increase, ~1,300 ordering accounts, ongoing investigator and real-world trials with initial data expected H2 2026, and a workforce reduction that produced $17.0M of restructuring charges.
Geron (Nasdaq: GERN) said members of management will present at three investor events in early March 2026: TD Cowen (fireside chat) on March 2, 2026 in Boston, Barclays (fireside chat) on March 10, 2026 in Miami, and Leerink Partners in-person meetings on March 11, 2026 in Miami.
A live and archived audio webcast of each fireside chat will be available via the Investors & Media section of Geron’s website at www.geron.com.
Geron (Nasdaq: GERN) granted inducement stock options effective Feb 17, 2026, to one newly hired employee for an aggregate of 742,500 shares.
The options carry an exercise price of $1.80 per share (closing price on grant date), a 10-year term, and vest over four years with 12.5% vesting at six months and the remainder in equal monthly installments over 42 months, subject to continued employment and plan terms.